AEHR Stock Rally Prices a Backlog Conversion Test

Aehr Test Systems has moved from an order-scarcity story to an execution-heavy one. Fiscal 2026 revenue fell 15.2%, yet management entered fiscal 2027 with $100.6 million of effective backlog and a revenue guide of $130 million to $150 million. The stock rally is the market treating that bridge as credible before Aehr has reported the revenue or margins.

At 11:33:06 a.m. Eastern on July 15, Alpaca’s IEX feed recorded AEHR at $92.65, up 28.59% from the previous completed-session close of $72.05. The shares had traded between $91.37 and $109.88 after opening at $98.155. That is a regular-session snapshot, not a final close; IEX volume is partial and is not used here as consolidated volume.

That changes the standard. The AEHR quote page now reflects a business expected to deliver a step-change in scale, not merely recover from a soft year. Aehr has supplied evidence for that expectation: record quarterly bookings, a materially larger order book, production ramps across several semiconductor end markets and a profitable fourth quarter. It has not yet supplied a fiscal year in which those pieces appear together in recognized revenue, GAAP earnings and cash generated from operations.

TECHi’s analysis is that investors are pricing an unusually fast backlog conversion cycle plus favorable order mix. The upside case is no longer difficult to describe. The work is in measuring whether system deliveries, proprietary contactor demand and package-level burn-in orders produce the operating leverage embedded in management’s outlook.

The market is paying for conversion, not the headline backlog

Aehr reported $80.6 million of backlog at its May 29 fiscal year-end and $100.6 million of “effective backlog” after including bookings received since that date. Quarterly bookings reached a record $60.7 million. Those figures, disclosed in the company’s fiscal 2026 results release, are the clearest support for the FY27 guide.

The coverage is substantial but incomplete. Effective backlog equals about 77% of the low end of the $130 million revenue forecast and 67% of the $150 million high end. That leaves roughly $29.4 million to $49.4 million of revenue that must come from orders outside the effective-backlog figure, depending on where results land. Management says the balance is supported by anticipated demand from existing production programs and that it is pursuing more orders.

This is analysis, not company guidance: backlog coverage makes the low end more tangible, but it does not erase delivery timing, customer acceptance or product-mix risk. Aehr does not disclose a quarter-by-quarter conversion schedule in the release. A tester that ships later than expected and a consumable contactor order that ships on schedule can carry different revenue and margin consequences even when the headline backlog remains intact.

That is why the stock’s next durable re-rating should come from conversion evidence. Investors need sequential revenue delivery against the guide, limited slippage in booked programs and a clear path from shipment growth to operating income. A larger order book is valuable; a repeatable cadence of accepted systems and follow-on consumables is more valuable.

A profitable fourth quarter sits beside a weaker fiscal year

The fourth quarter delivered a genuine operating improvement. Revenue rose to $18.835 million from $14.089 million a year earlier, an increase of 33.7%. GAAP net income reached $1.391 million, or $0.04 per diluted share, against a $2.899 million loss, or $0.10 per share, in the prior-year quarter. Non-GAAP net income was $3.552 million, or $0.11 per diluted share, compared with a $248,000 loss.

The SEC-filed earnings tables keep that quarter in proportion. Full-year revenue was $50.001 million, down from $58.968 million, while the GAAP net loss widened to $7.126 million from $3.910 million. Non-GAAP net income fell to about $900,000 from $4.6 million. Fiscal 2026 was not a growth year rescued by one soft line item; it was a contraction followed by a much stronger exit quarter.

That lower base amplifies the percentages in the new outlook. Revenue of $130 million to $150 million would be 2.6 to 3.0 times the FY26 result. Management also expects non-GAAP net income equal to 18% to 22% of revenue. At the endpoints, that framework implies roughly $23.4 million to $33 million of non-GAAP net income. The calculation illustrates how much operating leverage is being asked of a company that produced less than $1 million on the same basis last year.

Readers can track the reported base and subsequent quarters on TECHi’s AEHR financials page. The useful comparison is not whether each quarter beats the depressed year-ago period. It is whether cumulative revenue and non-GAAP profitability remain on pace for the annual ranges without an increasingly back-loaded delivery schedule.

Order mix will decide whether scale becomes margin

Aehr’s backlog is spread across more than one demand narrative. Management described wafer-level burn-in demand for AI processors, follow-on package-level burn-in business, silicon photonics capacity and a recovery in silicon carbide power semiconductors. Diversification can reduce dependence on a single end market, but these programs are not economically interchangeable.

The AI opportunity includes systems and proprietary WaferPak contactors used to test processors at the wafer level. Aehr says its lead AI production customer is ramping capacity and moving burn-in from the system level to wafer level for accelerators used in training and inference. Package-level exposure includes Sonoma systems supporting high-volume production burn-in. Silicon photonics customers are ordering automated wafer-level systems for optical interconnect applications.

Silicon carbide supplied a separate, tangible order signal. Aehr announced more than $8 million of new SiC wafer-level burn-in orders, including follow-on WaferPak contactors for a production customer and multiple contactors ordered directly by a large automotive company for device qualification. The orders indicate renewed customer activity after an automotive inventory correction, but the company did not identify the customers or provide a revenue-recognition timetable.

TECHi’s inference is that recurring contactor and follow-on production demand deserves more weight than evaluation language alone. A system placement can expand the installed base; proprietary consumables and additional capacity orders can then show that the customer’s production volume is real. The fiscal 2027 numbers become higher quality if growth is carried by several production programs rather than a small number of initial system shipments.

This is similar to the delivery-versus-demand distinction in TECHi’s ASML stock analysis and the backlog-to-valuation discipline applied to Vertiv’s AI cooling order book. In semiconductor infrastructure, an impressive backlog is the opening evidence. Shipment cadence, mix and customer expansion determine how much of it shareholders ultimately keep as earnings.

The AI benchmark is promising, but it is not production revenue

Aehr completed wafer-level burn-in benchmark testing with what it called a major supplier of AI accelerators, CPUs and network processors. The supplier expressed interest in pilot-production validation for the tested high-volume device and requested evaluation of a second device in parallel. Management said the benchmark results exceeded the prospective customer’s expectations.

That is technically meaningful progress. It also sits before a commercial milestone. The company did not announce a production purchase order from that unnamed supplier, disclose a contract value or say that the opportunity is included in effective backlog. Treating the benchmark as recognized AI revenue would move further than the evidence allows.

Investors have a concrete sequence to follow: pilot validation, a disclosed production order, system deployment, then repeat capacity or contactor demand. Technical validation proves performance, while an order establishes commercial commitment. Installation and acceptance determine revenue timing; repeat demand shows whether the device program is scaling.

The stock can continue to trade on the size of that opportunity, especially while AI reliability requirements are rising. But the FY27 guide should be judged primarily on booked and shipped business, not on the implied value of unnamed evaluations. A new customer win would be additive evidence, not a substitute for converting the existing $100.6 million.

The cash balance bought capacity to execute, not proof of execution

Aehr ended May with $116.5 million of cash, cash equivalents and restricted cash, up from $37.1 million at the end of February. That gives the company room to build inventory, support customer ramps and absorb working-capital timing. The source of the increase is essential context.

The fiscal-year cash-flow statement shows $97.395 million of net proceeds from sales of common stock while operating activities used $3.310 million of cash. An April SEC filing on the at-the-market program separately reported that Aehr had completed sales producing $60 million of gross proceeds under that facility. Period-end common shares outstanding increased to 32.480 million from 29.877 million a year earlier, an increase of about 8.7%.

The capital raise was not inherently negative. A supplier facing a rapid production ramp can benefit from funding secured before inventory and receivables consume cash. The mistake would be reading the larger balance as proof that operations already generated the resources needed for expansion. They did not during FY26.

Operating cash flow now becomes an important quality check alongside earnings. If revenue rises sharply, receivables and inventory may also rise, so a single quarter of cash use would not automatically invalidate the thesis. Persistent cash consumption after deliveries scale, however, would suggest that reported operating leverage is not translating cleanly into cash.

The next reports need to narrow three uncertainties

Delivery timing needs the closest watch. Investors should compare recognized revenue with the backlog available at the start of the year and listen for changes in customer schedules. A guide that stays intact while revenue repeatedly shifts toward later quarters carries more risk than one supported by steady conversion.

Order composition also matters. Aehr has described production activity across AI, silicon photonics and silicon carbide, but investors need enough disclosure to distinguish repeat orders from early evaluation work. Growth supported by contactor replenishment, installed-base expansion and multiple production customers would be more durable than growth concentrated in a few large systems.

GAAP operating leverage completes the picture. The company’s 18% to 22% target is a non-GAAP net-income margin, which excludes stock-based compensation and acquisition-related adjustments. The Q4 GAAP profit was encouraging, but the full-year GAAP loss shows why reconciliation still matters. Watch gross margin, operating expenses, stock compensation and cash from operations as revenue scales.

Short-term traders can use TECHi’s AEHR technicals page to monitor a volatile post-earnings setup. Long-term shareholders have a different job: measure the business against the conversion math rather than treating the first price reaction as confirmation of the entire FY27 plan.

Risk and outlook

The bullish reading is grounded in facts. Aehr has a record order quarter, effective backlog equal to most of its annual revenue target, a profitable Q4, more than $8 million of fresh SiC orders and active production ramps in AI and silicon photonics. Its cash balance provides room to support a much larger operation.

The risks are equally concrete. Fiscal 2026 revenue contracted, the year produced a GAAP loss and operating cash use, part of the new AI opportunity remains at the benchmark or pilot-interest stage, customers are unnamed, and the revenue guide requires a dramatic increase from the latest full-year base. Equity issuance strengthened liquidity while diluting existing ownership.

The rally therefore does not settle the investment case; it raises the standard for the next few reports. Aehr now needs to show that booked demand converts on schedule, that production-oriented orders become a larger share of the mix and that higher revenue produces both operating income and cash. If those signals arrive together, the $100.6 million backlog can mark the start of a larger earnings base. If they separate, the market will have paid for conversion before the company delivered it.